Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5825399 | Clinical Therapeutics | 2013 | 10 Pages |
Abstract
The fixed-dose combination of ASA and clopidogrel 100 mg/75 mg did not meet the regulatory criteria for bioequivalence as defined by the Korea Food and Drug Administration. Both formulations were well tolerated in these healthy male Korean subjects. ClinicalTrials.gov Identifier: NCT01448330
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Jin Ah MD, PhD, Tae-Eun MD, PhD, Jung-Ryul MD, PhD, Min-Ji MS, Wooseong MD, PhD, Kyung-Mi PhD, Soo-Youn MD, PhD, Jae-Wook MD, PhD,